Ahmadi M Amir, Lim Jennifer I
University of Illinois at Chicago, Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, IL 60612, Chicago USA.
Expert Opin Pharmacother. 2008 Dec;9(17):3045-52. doi: 10.1517/14656560802473480.
Age-related macular degeneration is the leading cause of blindness in the developed world. The number of persons with vision loss from age-related macular degeneration is projected to increase dramatically over the next few decades. Therefore, effective therapeutic and prophylactic agents are greatly needed.
This article will discuss some of the newer treatment strategies that may help to reduce the incidence of visual loss from age-related macular degeneration. Some of these therapies and strategies can be implemented today, while many are hypothetical based on current laboratory data and ongoing clinical trials.
A review of the literature and ongoing clinical trials was undertaken.
Current therapies using antioxidants for prevention of the progression of age-related macular degeneration and anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration have given us tools for tackling this disease better and reducing the number of patients with vision loss. Combinations of some of the existing treatments and new forms of therapy may yet further decrease the treatment burden in the future.
年龄相关性黄斑变性是发达国家失明的主要原因。预计在未来几十年中，因年龄相关性黄斑变性导致视力丧失的人数将急剧增加。因此，迫切需要有效的治疗和预防药物。
本文将讨论一些可能有助于降低年龄相关性黄斑变性导致视力丧失发生率的新治疗策略。其中一些治疗方法和策略目前即可实施，而许多则基于当前实验室数据和正在进行的临床试验尚属假设。
对文献和正在进行的临床试验进行了综述。
目前使用抗氧化剂预防年龄相关性黄斑变性进展的疗法以及用于新生血管性年龄相关性黄斑变性的抗血管内皮生长因子疗法，为我们更好地应对这种疾病和减少视力丧失患者数量提供了工具。未来，一些现有治疗方法与新治疗形式的联合应用可能会进一步减轻治疗负担。
